Metsera M&A melee & Tidmarsh’s ouster from FDA — a BioCentury podcast

Novo Nordisk bid upends Pfizer’s plans for smooth takeout of standout U.S. obesity play

Novo Nordisk A/S’s unsolicited $8.5 billion bid for Metsera Inc. has thrown a wrench into Pfizer Inc.’s plans to return to the obesity race via its acquisition of the New York-based start-up. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the details of the competing bids and what’s at stake for the pair of suitors.

The analysts also assess the reasons behind the abrupt departure of Center for Drug Evaluation and Research Director George Tidmarsh from FDA and a surge in activity on the Hong Kong stock exchange. 

For more of BioCentury’s analysis on obesity and Washington, head to the Hot Topics page. This episode of the BioCentury This Week podcast is brought to you by Voyager Therapeutics.